Contraindicated (1)bortezomib will boost the level or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or average CYP2C19 inhibitors may possibly increase mavacamten systemic publicity, leading to heart failure resulting from systolic dysfunction.Unlock 38% extra drug discovery time and remove choice-p